Home / Intelligence / Case Studies / Global Value Messaging and P&MA Strategy for a CAR-T Cell Therapy
Trinity completed an engagement to support the successful launch of a CAR-T cell therapy with distinct clinical profile in a competitive landscape.
Geographic Scope: 
Client Situation
The client asked Trinity to develop and externally validate global payer value messages and the associated evidence set for their CAR T cell therapy. They also required support with developing a robust global pricing and market access strategy for their asset.
Trinity’s Solution
Trinity conducted focus groups and In-Depth-Interviews (IDIs) with key payer and provider stakeholders in scope markets to understand the evolving cell therapy landscape and identify unique opportunities and challenges that are relevant for “one-time” therapies.
Deliverables
- Outputs from internal workshops summarizing alignment among cross-functional stakeholders
- Refined value story and supporting exhibits for the CAR-T cell therapy
- Key learnings and actionable recommendations informing pricing and market access strategy
Project Outcomes & Impact
The client was provided with an impactful value, access, and pricing strategy for a CAR-T cell therapy product to successfully convey differentiation in an increasingly crowded and competitive environment.
Related Intelligence
Webinars
Annual State of Global Market Access Webinar
Available On Demand
Trinity Life Sciences is pleased to release our highly anticipated white paper, the Annual State of Global Market Access. This year’s white paper focuses on six key global market access trends and provides payer perspectives on these trends. We explore the consequences of new therapeutic advances and policies aiming to control costs globally and the […]
Watch Now
White Papers
Annual State of Global Market Access
In 2023, the life sciences industry saw key therapeutic advances in sickle cell disease, obesity/weight management, and Duchenne muscular dystrophy, among others, and the continued approvals of therapies with cutting edge mechanisms, including the first CRISPR therapy. While 2022 was characterized by accelerated development processes and the rapid evolution of therapeutic standards, 2023 featured increased […]
Read More
Blog
Cell and Gene Therapies: Six Global Trends We Are Watching in 2024
2023 was a busy year for cell and gene therapies (C>). There were regulatory approvals in the U.S. and EU, including both in rare pediatric conditions with no current effective options (e.g., Duchenne muscular dystrophy (DMD)), as well as in indications where competition is better established (e.g., hemophilia A and B). Towards the end of […]
Read More